238 related articles for article (PubMed ID: 18458279)
1. Narrative review: buprenorphine for opioid-dependent patients in office practice.
Sullivan LE; Fiellin DA
Ann Intern Med; 2008 May; 148(9):662-70. PubMed ID: 18458279
[TBL] [Abstract][Full Text] [Related]
2. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
[TBL] [Abstract][Full Text] [Related]
3. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.
Bonhomme J; Shim RS; Gooden R; Tyus D; Rust G
J Natl Med Assoc; 2012; 104(7-8):342-50. PubMed ID: 23092049
[TBL] [Abstract][Full Text] [Related]
4. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Bishop B; Gilmour J; Deering D
Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
[TBL] [Abstract][Full Text] [Related]
5. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
Srivastava A; Kahan M; Nader M
Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
[TBL] [Abstract][Full Text] [Related]
6. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
Strain EC; Stoller K; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2000 Mar; 148(4):374-83. PubMed ID: 10928310
[TBL] [Abstract][Full Text] [Related]
7. Opioid dependence: rationale for and efficacy of existing and new treatments.
Fiellin DA; Friedland GH; Gourevitch MN
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
[TBL] [Abstract][Full Text] [Related]
8. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
9. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.
Crist RC; Clarke TK; Ang A; Ambrose-Lanci LM; Lohoff FW; Saxon AJ; Ling W; Hillhouse MP; Bruce RD; Woody G; Berrettini WH
Neuropsychopharmacology; 2013 Sep; 38(10):2003-10. PubMed ID: 23612435
[TBL] [Abstract][Full Text] [Related]
10. Opioid dependence treatment, including buprenorphine/naloxone.
Raisch DW; Fye CL; Boardman KD; Sather MR
Ann Pharmacother; 2002 Feb; 36(2):312-21. PubMed ID: 11847954
[TBL] [Abstract][Full Text] [Related]
11. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
Saunders EC
Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
[No Abstract] [Full Text] [Related]
12. Practical considerations for the clinical use of buprenorphine.
Jones HE
Sci Pract Perspect; 2004 Aug; 2(2):4-20. PubMed ID: 18552728
[TBL] [Abstract][Full Text] [Related]
13. Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
Leshner AI
Drug Alcohol Depend; 2003 May; 70(2 Suppl):S103-4. PubMed ID: 12738354
[No Abstract] [Full Text] [Related]
14. Office-based treatment of opioid-dependent patients.
Ferner RE; Daniels AM
N Engl J Med; 2003 Jan; 348(1):81-2; author reply 81-2. PubMed ID: 12510051
[No Abstract] [Full Text] [Related]
15. Buprenorphine maintenance: a new treatment for opioid dependence.
Collins GB; McAllister MS
Cleve Clin J Med; 2007 Jul; 74(7):514-20. PubMed ID: 17682629
[TBL] [Abstract][Full Text] [Related]
16. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
[TBL] [Abstract][Full Text] [Related]
17. Use and misuse of opioid replacement therapies: a Queensland study.
Smirnov A; Kemp R
Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
[TBL] [Abstract][Full Text] [Related]
18. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.
Chakrabarti A; Woody GE; Griffin ML; Subramaniam G; Weiss RD
Drug Alcohol Depend; 2010 Mar; 107(2-3):253-6. PubMed ID: 19948382
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine and naloxone for heroin dependence.
Johnson RE; McCagh JC
Curr Psychiatry Rep; 2000 Dec; 2(6):519-26. PubMed ID: 11123005
[TBL] [Abstract][Full Text] [Related]
20. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
Fingerhood MI; King VL; Brooner RK; Rastegar DA
Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
